Chamberlain University
MRAHP · 543D
★ ★
C College of Nursing & Public Health
EST. 1889
EXTRAORDINARY CARE · EXTRAORDINARY NURSES
D345 — Advanced Pharmacology Examination
N E U R OT RA N S M I T T E RS , PSYC H O P H A R M ACO LO G Y & C L I N I C A L T H E RA P E U T I CS
INSTITUTION Chamberlain University COURSE CODE D345
PROGRAM Doctor of Nursing Practice — ACADEMIC YEAR
Advanced Pharmacology
EXAM TITLE D345 — Advanced Pharmacology TOTAL QUESTIONS 250+ Questions
Examination
COURSE TITLE Advanced Pharmacology for FORMAT Multiple Choice — Select the
Nursing Practice Single Best Answer
EXAMINATION INSTRUCTIONS
▸ Select the single best answer for each question.
▸ Neurotransmitter systems, psychopharmacology, withdrawal management, antipsychotics, mood
stabilizers, anxiolytics, and ADHD medications are all testable content.
▸ CYP450 interactions, DEA scheduling, therapeutic ranges, and serious adverse effects are emphasized.
▸ Correct answers and clinical rationales appear below each question for board preparation.
▸ All pharmacological data reflects current evidence-based clinical guidelines.
, SECTION I — ADVANCED PHARMACOLOGY:
NEUROTRANSMITTERS THROUGH CLINICAL Questions 1 – 250+
THERAPEUTICS
1. Glutamate is best described as the:
A. Main inhibitory neurotransmitter that reduces neuronal excitability
B. Main excitatory neurotransmitter involved in learning and memory
C. Neurotransmitter primarily involved in mood regulation and sleep
D. Inhibitory neurotransmitter in the spinal cord and brainstem
CORRECT ANSWER B — Main excitatory neurotransmitter involved in learning and memory
RATIONALE Glutamate is the primary excitatory neurotransmitter in the central nervous
system — it binds to NMDA, AMPA, and kainate receptors, promoting neuronal
depolarization and firing. It is critical for synaptic plasticity, long-term
potentiation (LTP), and cognitive functions including learning and memory. GABA
(Choice A) is the main inhibitory neurotransmitter. Serotonin (Choice C) regulates
mood and sleep. Glycine (Choice D) is an inhibitory neurotransmitter in the spinal
cord and brainstem. Glutamate dysfunction is implicated in schizophrenia,
Alzheimer's disease, and excitotoxicity following stroke. Understanding excitatory
vs. inhibitory neurotransmitter systems is foundational to psychopharmacology.
,2. Lithium is considered the gold standard treatment for:
A. Generalized anxiety disorder
B. Bipolar disorder, especially for mania and mood stabilization, and reducing suicidality
C. Major depressive disorder with psychotic features
D. Attention-deficit hyperactivity disorder
CORRECT ANSWER B — Bipolar disorder, especially for mania and mood stabilization, and
reducing suicidality
RATIONALE Lithium is the gold standard mood stabilizer for bipolar disorder — it treats acute
mania, prevents both manic and depressive episodes, and is the only mood
stabilizer with proven anti-suicidal effects. Its therapeutic range is narrow (0.6–1.2
mEq/L), requiring regular serum monitoring. Baseline labs include thyroid
function, renal function (creatinine, BUN), and pregnancy test. Lithium is
contraindicated in severe renal disease and requires caution with NSAIDs,
diuretics, and ACE inhibitors. Toxicity signs progress from
nausea/vomiting/tremor (early) to seizures, arrhythmias, and coma (late).
Lithium's unique anti-suicidal property makes it irreplaceable in bipolar
treatment despite its narrow therapeutic index.
, 3. The therapeutic range for Lithium is:
A. 0.1–0.5 mEq/L
B. 0.6–1.2 mEq/L
C. 1.5–2.5 mEq/L
D. 50–100 mcg/mL
CORRECT ANSWER B — 0.6–1.2 mEq/L
RATIONALE Lithium's therapeutic range is 0.6–1.2 mEq/L — levels above 1.5 mEq/L approach
toxicity. Regular monitoring (every 3–6 months after stabilization) is essential due
to the narrow therapeutic index. Early toxicity signs include nausea, vomiting,
diarrhea, tremor, and confusion; late toxicity includes seizures, arrhythmias, and
renal damage. Choice D (50–100 mcg/mL) is the therapeutic range for Depakote
(valproic acid), not lithium. Lithium levels are affected by sodium balance —
hyponatremia increases lithium retention and toxicity risk. Patient education
must emphasize adequate hydration and salt intake while avoiding NSAIDs and
thiazide diuretics that can increase lithium levels dangerously.
MRAHP · 543D
★ ★
C College of Nursing & Public Health
EST. 1889
EXTRAORDINARY CARE · EXTRAORDINARY NURSES
D345 — Advanced Pharmacology Examination
N E U R OT RA N S M I T T E RS , PSYC H O P H A R M ACO LO G Y & C L I N I C A L T H E RA P E U T I CS
INSTITUTION Chamberlain University COURSE CODE D345
PROGRAM Doctor of Nursing Practice — ACADEMIC YEAR
Advanced Pharmacology
EXAM TITLE D345 — Advanced Pharmacology TOTAL QUESTIONS 250+ Questions
Examination
COURSE TITLE Advanced Pharmacology for FORMAT Multiple Choice — Select the
Nursing Practice Single Best Answer
EXAMINATION INSTRUCTIONS
▸ Select the single best answer for each question.
▸ Neurotransmitter systems, psychopharmacology, withdrawal management, antipsychotics, mood
stabilizers, anxiolytics, and ADHD medications are all testable content.
▸ CYP450 interactions, DEA scheduling, therapeutic ranges, and serious adverse effects are emphasized.
▸ Correct answers and clinical rationales appear below each question for board preparation.
▸ All pharmacological data reflects current evidence-based clinical guidelines.
, SECTION I — ADVANCED PHARMACOLOGY:
NEUROTRANSMITTERS THROUGH CLINICAL Questions 1 – 250+
THERAPEUTICS
1. Glutamate is best described as the:
A. Main inhibitory neurotransmitter that reduces neuronal excitability
B. Main excitatory neurotransmitter involved in learning and memory
C. Neurotransmitter primarily involved in mood regulation and sleep
D. Inhibitory neurotransmitter in the spinal cord and brainstem
CORRECT ANSWER B — Main excitatory neurotransmitter involved in learning and memory
RATIONALE Glutamate is the primary excitatory neurotransmitter in the central nervous
system — it binds to NMDA, AMPA, and kainate receptors, promoting neuronal
depolarization and firing. It is critical for synaptic plasticity, long-term
potentiation (LTP), and cognitive functions including learning and memory. GABA
(Choice A) is the main inhibitory neurotransmitter. Serotonin (Choice C) regulates
mood and sleep. Glycine (Choice D) is an inhibitory neurotransmitter in the spinal
cord and brainstem. Glutamate dysfunction is implicated in schizophrenia,
Alzheimer's disease, and excitotoxicity following stroke. Understanding excitatory
vs. inhibitory neurotransmitter systems is foundational to psychopharmacology.
,2. Lithium is considered the gold standard treatment for:
A. Generalized anxiety disorder
B. Bipolar disorder, especially for mania and mood stabilization, and reducing suicidality
C. Major depressive disorder with psychotic features
D. Attention-deficit hyperactivity disorder
CORRECT ANSWER B — Bipolar disorder, especially for mania and mood stabilization, and
reducing suicidality
RATIONALE Lithium is the gold standard mood stabilizer for bipolar disorder — it treats acute
mania, prevents both manic and depressive episodes, and is the only mood
stabilizer with proven anti-suicidal effects. Its therapeutic range is narrow (0.6–1.2
mEq/L), requiring regular serum monitoring. Baseline labs include thyroid
function, renal function (creatinine, BUN), and pregnancy test. Lithium is
contraindicated in severe renal disease and requires caution with NSAIDs,
diuretics, and ACE inhibitors. Toxicity signs progress from
nausea/vomiting/tremor (early) to seizures, arrhythmias, and coma (late).
Lithium's unique anti-suicidal property makes it irreplaceable in bipolar
treatment despite its narrow therapeutic index.
, 3. The therapeutic range for Lithium is:
A. 0.1–0.5 mEq/L
B. 0.6–1.2 mEq/L
C. 1.5–2.5 mEq/L
D. 50–100 mcg/mL
CORRECT ANSWER B — 0.6–1.2 mEq/L
RATIONALE Lithium's therapeutic range is 0.6–1.2 mEq/L — levels above 1.5 mEq/L approach
toxicity. Regular monitoring (every 3–6 months after stabilization) is essential due
to the narrow therapeutic index. Early toxicity signs include nausea, vomiting,
diarrhea, tremor, and confusion; late toxicity includes seizures, arrhythmias, and
renal damage. Choice D (50–100 mcg/mL) is the therapeutic range for Depakote
(valproic acid), not lithium. Lithium levels are affected by sodium balance —
hyponatremia increases lithium retention and toxicity risk. Patient education
must emphasize adequate hydration and salt intake while avoiding NSAIDs and
thiazide diuretics that can increase lithium levels dangerously.
